Gossamer Bio, Inc. 8K

Gossamer Bio, Inc. finalized its exchange offer for its 2027 convertible notes, resulting in most notes being exchanged into new 2030 secured convertible notes and equity securities, with $18.948 million of the old notes remaining outstanding.

Gossamer Bio, Inc. announced the final results of its previously launched exchange offer and consent solicitation for its 5.00% Convertible Senior Notes due 2027, under which $181.052 million aggregate principal amount of notes had been validly tendered by the June 2, 2026 extended early tender date, enabling early settlement on June 4, 2026 of new 7.50% Convertible Senior Secured First Lien Notes due 2030, equity securities (common stock or prefunded warrants) and purchase warrants, and allowing the company to execute a supplemental indenture that removed substantially all restrictive covenants and certain events of default on the old notes; as of the final deadline on June 16, 2026, no additional notes were tendered, leaving $18.948 million principal amount of the existing convertible notes outstanding.

Filing Facts

CIK

1728117

Ticker

-

Form

8K

Source Type

sec

Accession

0001728117-26-000054

Alert Tier

7